Celldex To Report Second Quarter 2014 Financial Results And Host Corporate 2014 Objectives Update Call

HAMPTON, N.J., July 18, 2014 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) will release second quarter 2014 financial results on Wednesday, August 6, 2014 after the U.S. financial markets close. Celldex executives will host a conference call at 4:30 p.m. ET on the same day to review the second quarter 2014 financial results and to provide an update on key research and development and business objectives for the remainder of 2014.

The conference call and presentation will be webcast live over the Internet and can be accessed by going to the "Events & Presentations" page under the "Investors & Media" section of the Celldex Therapeutics website at www.celldex.com . The call can also be accessed by dialing (866) 743-9666 (within the United States) or (760) 298-5103 (outside the United States). The passcode is 75485305.

A replay of the call will be available approximately two hours after the live call concludes through August 13, 2014. To access the replay, dial (855) 859-2056 (within the United States) or (404) 537-3406 (outside the United States). The passcode is 75485305. The webcast will also be archived on the Company's website.

About Celldex Therapeutics, Inc.

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Visit www.celldex.com .
CONTACT: Sarah Cavanaugh         Vice President of Investor Relations &         Corp Communications         Celldex Therapeutics, Inc.         (781) 433-3161         scavanaugh@celldex.com

Celldex Therapeutics logo

If you liked this article you might like

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

Celldex Therapeutics (CLDX) Stock Up on Q2 Results

Celldex Therapeutics (CLDX) Is Strong On High Volume Today